RXRX
Recursion Pharmaceuticals Inc
NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY
$3.30
-3.23% today
Updated 2026-04-29
Market cap
$1.80B
P/E ratio
—
P/S ratio
24.12x
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$3 – $7
Volume
14.3M
Recursion Pharmaceuticals Inc (RXRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.71M | $3.41M | $10.00M | $39.68M | $43.88M | $58.84M | $74.68M |
| Revenue growth (YoY) | — | +99.5% | +193.0% | +296.8% | +10.6% | +34.1% | +26.9% |
| Cost of revenue | $45.81M | $63.32M | $9.10M | $48.27M | $42.59M | $45.24M | $120.95M |
| Gross profit | $-44.10M | $3.41M | $10.00M | $-8.59M | $1.29M | $13.60M | $-46.27M |
| Gross margin | -2577.3% | 100.0% | 100.0% | -21.7% | 2.9% | 23.1% | -62.0% |
| R&D | $45.81M | $63.32M | $135.27M | $155.70M | $241.23M | $314.42M | $425.27M |
| SG&A | $18.95M | $25.26M | $57.68M | $81.60M | $110.82M | $178.18M | $176.59M |
| Operating income | $-62.44M | $-84.61M | $-182.78M | $-245.73M | $-350.06M | $-479.00M | $-648.13M |
| Operating margin | -3649.4% | -2479.2% | -1827.8% | -619.3% | -797.8% | -814.1% | -867.9% |
| EBITDA | $-58.34M | $-81.70M | $-174.37M | $-233.97M | $-307.63M | $-426.72M | $-559.38M |
| EBITDA margin | -3409.5% | -2393.9% | -1743.7% | -589.6% | -701.1% | -725.2% | -749.0% |
| EBIT | $-61.88M | $-85.65M | $-182.78M | $-245.73M | $-332.03M | $-463.22M | $-643.09M |
| Interest expense | $635000.00 | $1.36M | $2.95M | $55000.00 | $97000.00 | $1.57M | $1.81M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-62.52M | $-87.01M | $-178.07M | $-239.42M | $-328.07M | $-463.66M | $-644.76M |
| Net income growth (YoY) | — | -39.2% | -104.7% | -34.5% | -37.0% | -41.3% | -39.1% |
| Profit margin | -3654.3% | -2549.3% | -1780.7% | -603.4% | -747.7% | -788.0% | -863.4% |